Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes

计划入组 5 人 · 首次发布于 2023 年 1 月 13 日

A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes

计划入组 321 人 · 首次发布于 2021 年 8 月 24 日

Clinical Relevance of Typing HLA-DR7-DQ2

计划入组 92 人 · 首次发布于 2013 年 3 月 19 日

HLA-DQ2/DQ8 inhibitors (Provid)

HLA-DQ2 peptide vaccine (ImmusanT)

HLA-DR3 antigen inhibitor (ImmunoMolecular Therapeutics)

DC2 Healthcare, LLC

United States

HLT, Inc.

United States

LABORATOIRE HRA PHARMA

Spain

Diamyd Immunotherapy Shows Robust Efficacy in Type 1 Diabetes Patients with HLA DR3-DQ2

Diamyd Immunotherapy Shows Robust Efficacy in Type 1 Diabetes Patients with HLA DR3-DQ2

Diamyd Medical Highlights Precision Medicine Approach for Type 1 Diabetes at ISPAD and IDS Conferences